RECORDING: Professionals’ Conference – 23 June 2023
A recording of the Retina UK Professionals' Conference on 23 June 2023. The Conference was held at the University of Westminster, Marylebone Campus in London and online.
Search
Search results
A genetic diagnosis for RP can give rise to unexpected surprises
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
Disability sector calling for cost of living support
Retina UK has joined with more than 80 disability charities who have today written to the Chancellor calling for urgent support with the cost of living for disabled people.
New Eye Care Support Pathway wins cross-sector backing
New Eye Care Support Pathway wins cross-sector backing for transforming the way people with care needs and sight loss are helped emotionally and practically.
Retina UK awarded prestigious quality standard
The Royal National Institute of Blind People (RNIB) have awarded Retina UK the Visibly Better Employer quality standard.
Research grant awards worth £870K announced
Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.
Vitamin A supplements provides no vision benefit to RP patients
Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Nanoscope Announces topline results from randomised phase 2B trial of MCO-010 for retinitis pigmentosa
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).